Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) projects its whole-olive polyphenol nutraceutical Oliv18™ to generate over $6 million in incremental annual U.S. revenue within 12–18 months, with about $4.3 million gross profit at an estimated 72% gross margin, according to Cosmos Health.
Oliv18™, part of the company’s “18 Series,” targets the U.S. cardiovascular health and antioxidant supplement categories via a staged rollout, starting with direct-to-consumer e-commerce and later selected retail channels. Cosmos Health notes its forecast is based on internal assumptions and successful execution of commercialization plans.
Positive
- Projected Oliv18™ U.S. annual revenue over $6 million in 12–18 months
- Expected Oliv18™ gross profit approximately $4.3 million at 72% gross margin
- Staged U.S. rollout starting with direct-to-consumer e-commerce, then selected retail channels
- Oliv18™ extends Cosmos Health’s 18 Series into two U.S. wellness categories
Negative
- Revenue and profit figures are projections based on internal assumptions, not guaranteed results
- Forecast depends on continued execution of Cosmos Health’s commercialization plans for Oliv18™
Details
News Market Reaction – COSM
On Aug 24, the day this news came out, COSM closed 6.73% below the previous close. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner recorded 14 alerts for this stock that day. Relative volume reached 1.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 24 session.
Key Figures
- Incremental annual U.S. revenue
- over $6 million
- Oliv18 projection within the next 12 to 18 months
- Gross profit
- $4.3 million
- Oliv18 projection within the next 12 to 18 months
- Expected gross margin
- approximately 72%
- Oliv18 projection
- Projection timeframe
- 12 to 18 months
- Expected period for incremental annual U.S. revenue
- U.S. cardiovascular health supplements market
- $2.11 billion
- 2024 estimate
- U.S. cardiovascular health supplements market
- $3.27 billion
- 2030 projection
- U.S. antioxidants market
- $1.66 billion
- 2025 valuation
- U.S. antioxidants market
- $3.18 billion
- 2035 projection
Historical Context
-
Saudi distribution agreement included an initial purchase order for 126,000 units.
-
Net loss widened despite record revenue and adjusted gross-profit growth.
-
Company advanced an AI-enabled subscription platform across B2C and B2B channels.
-
Company reported an additional 274,000 share repurchase under its existing program.
-
Total repurchases surpassed 4.8 million shares under the authorized program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
polyphenol medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over
Oliv18™ is part of the Company's "18 Series," a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced through a
The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.
According to Grand View Research, the U.S. cardiovascular health supplements market was estimated at
Greg Siokas, CEO of Cosmos Health, stated: "Oliv18™ extends our 18 Series into two established categories in consumer wellness, where demand continues to shift toward products supported by scientific substantiation. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.